| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Reproductive Sciences,5 Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon 97006
Department of Obstetrics & Gynecology6
Department of Physiology and Pharmacology,7 Oregon Health & Science University, Portland, Oregon 97239
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
corpus luteum, corpus luteum function, luteinizing hormone, ovary, progesterone
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Since the discovery of VEGF in 1989 as a 40 000- to 46 000-Mr, disulfide-linked, dimeric glycoprotein, investigators have determined that at least seven isoforms of VEGF displaying different biochemical properties can be generated by alternative splicing from a single gene [5, 9]. The human isoforms include proteins of 206, 189, 183, 165, 148, 145, and 121 amino acids per monomer that differ in their ability to bind to heparin and to specific VEGF receptors/coreceptors (neuropilins). In addition, increasing evidence suggests dynamic expression of different isoforms within tissues [10] and that the different isoforms may promote specific functions in certain vascular beds [11]. Limited evidence indicates hormonal regulation of selected VEGF isoforms. For example, Ancelin et al. [12] reported that stromal cells in the human endometrium express mRNAs for the VEGF 189, 165 and 121 isoforms and that progesterone (P4) exposure selectively increases expression of VEGF 189 mRNA.
To date, little detailed information exists regarding the expression or regulation of VEGF isoforms in the ovary, particularly in the CL. Our group [13, 14] and others [15, 16] have provided evidence that the gonadotropic hormone, LH, is a major stimulator of VEGF production by granulosa cells in the ovulatory, luteinizing follicle, but the control of VEGF production in the CL by hormonal or local factors remains unknown. Therefore, experiments were designed, using the rhesus monkey as a primate model, to determine the following: 1) which VEGF isoforms are expressed by the primate CL, 2) if the VEGF isoforms are selectively expressed during the CL life span in the menstrual cycle, and 3) whether LH and/or hypoxia (the primary stimulant of VEGF production in various vascular beds [17]) increases VEGF production by macaque luteal cells at various stages of the CL life span.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Animal protocols were approved by the Oregon National Primate Research Center Animal Care and Use Committee and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Daily blood samples were collected by saphenous venipuncture from adult, female rhesus monkeys (Macaca mulatta) exhibiting regular menstrual cycles; samples were collected beginning 6 days after menses and continuing to the time of lutectomy. Serum estradiol and P4 levels were determined using ELISA (Elecsys 2010; Roche Diagnostics, Indianapolis, IN) as described previously [18]. The first day of low (<100 pg/ml) serum estradiol levels following the midcycle estradiol peak corresponds with the day after the LH surge and, therefore, was considered to be Day 1 of the luteal phase [19].
The CL (n = 4–6 per stage of the luteal phase) was removed from anesthetized rhesus monkeys [20] during the early (3–5 days post-LH surge), mid (6–8 days post-LH surge), mid-late (10–12 days post-LH surge), and late (14–16 days post-LH surge) luteal phase of the menstrual cycle and very late in menstruation (17–18 days post-LH surge). This provided tissues at intervals representing developing, functioning, on the verge of regressing, regressing, and regressed CL, respectively [20]. The individual CL were divided into three portions, two which were immediately frozen in liquid nitrogen and stored at –80°C for isolation of either total RNA or protein; the third portion was processed for other histological studies [18]. Other freshly isolated CL (n = 4–6 per stage of the luteal phase) also were transferred to the laboratory for preparation of dispersed luteal cells.
RNA Isolation and Reverse Transcription
Total RNA from individual CL collected at the different stages of the luteal phase was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The RNA was treated with 1 µg of DNase (Invitrogen). Reverse transcription (RT) was performed for 2 h at 37°C in a 20-µl reaction volume using Moloney murine leukemia virus reverse transcriptase (Invitrogen) as described previously [21].
Cloning and Sequencing of Macaque VEGF mRNAs
Primers corresponding to regions in VEGF exon 4 and exon 8 were used in a polymerase chain reaction (PCR) system to amplify VEGF cDNAs for mRNAs encoding isoforms 206, 189, 183, 165, 145, and 121 (Fig. 1). The primer sequences were as follows: sense, 5'-TTATGCGGATCAAACCTCACCAAGGC-3'; antisense, 5'-TGTGGGTGGGTGTGTCTA-3'. The products obtained were cloned into a plasmid-based vector (pGEM; Invitrogen) and transformed into the appropriate bacterial host vector (Escherichia coli strain XL-1' Blue; Stratagene, San Diego, CA). Plasmids were purified from individual clones as described previously [22]. The plasmids were sequenced in the Molecular and Cellular Biology Core facility of the Oregon National Primate Research Center using an ABI 377 automated sequencer, with T7 and SP6 primers (Applied Biosystems, Foster City, CA). The sequence data were analyzed for homology to previously characterized genes deposited in the National Center for Biotechnology Informatics (NCBI) database using the Basic Local Alignment Tool (BLAST) program.
|
Rapid Amplification of cDNA Ends for VEGF mRNAs
Rapid amplification of cDNA ends (RACE) was performed using the Invitrogen GeneRacer cDNA Amplification Kit to identify the 3'-end of the VEGF cDNA. Touchdown PCR parameters were according to the manufacturer's instructions. A cDNA template was created from polyA+ RNA isolated from a pool of CL that included tissues from all stages of the luteal phase. For 3'-RACE, the Universal Primer Mix (Invitrogen) was used in combination with the VEGF sense primer corresponding to a region in exon 2 (5'-CCATGGCAGAAGGAGGAGGGCAGAATC-3'). Products were analyzed by electrophoresis using a 1% agarose gel and visualized by ethidium bromide staining. Products were sequenced and compared to the macaque and human VEGF sequence data as described in the previous section.
PCR Analysis of VEGF 165 and 121 mRNAs
Primer sets that specifically amplify cDNA for the detectable VEGF transcripts were used in semiquantitative RT-PCR experiments using peptidylprolyl isomerase A (PPIA; also known as cyclophilin A) mRNA as an internal control. For the VEGF 165 transcript, primers (Fig. 1) were designed at the junctions of exons 5 and 7 (sense, 5'-CAAGAAAATCCCTGTGGG-3') and exons 8 and 7 (antisense, 5'-TTGTCACATCTGCAAGTA-3'). For the VEGF 121 variant (Fig. 2), primers were designed using an area of exon 4 (sense, 5'-TTATGCGGATCAAACCTCACCAAGG-3') and the junctions of exons 8 and 5 (antisense, 5'-CTTGTCACATTTTTCTTGTCT-3'). The primer sequences were based on the rhesus macaque VEGF cDNA data provided by the cloning experiments. As positive controls and to prove the specificity of the VEGF primers, the 165 and 121 plasmids obtained in the cloning experiments also were included in the experiments.
|
Validation of the RT-PCR assay was performed as described previously [23]. The PCR was carried out in a 25-µl volume containing an empirically determined amount of the RT reaction, 1 µl of the 10 mM specific primer set, 2.5 µl of 10x strength Taq buffer (BD Biosciences Clontech, Palo Alto, CA), 1 µl of 10 mM deoxy-NTPs, and 0.75 µl of Advantage 2 Taq (BD Biosciences Clontech). The reaction was initiated at 94°C for 1.5 min, followed by 94°C for 30 sec, 56°C for 30 sec, and 72°C for 2 min for 35 cycles, and then a final extension at 72°C for 5 min. Aliquots of the PCR products were electrophoresed through a 1.4% agarose gel stained with 0.1 µg/ml of ethidium bromide. The PPIA mRNA was used as an internal control, because no apparent changes in macaque CL expression of this gene were observed at any stage of the menstrual cycle [24]. Gels were visualized on an ultraviolet transilluminator and photographed. The gel bands were quantified by densitometry using Quantity One software (Bio-Rad, Hercules, CA); both VEGF and PPIA mRNAs showed a linear response over defined PCR cycles.
Western Blot Analysis of VEGF-A Proteins
Proteins were extracted from individual CL; the protein extracts were subjected to electrophoresis on 15% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes as reported previously [25]. Goat polyclonal anti-human VEGF (catalog no. AF-293-NA; R&D Systems, Minneapolis, MN) that recognizes both the 165 and 121 isoforms was used as primary antibody (1:1000, 1 h). Protein bands were visualized by incubating the blots for 1 h with peroxidase-conjugated rabbit anti-goat immunoglobulin G (1:4000 dilution; Zymed Laboratories, San Francisco, CA). Negative controls were performed in the absence of the primary antibody. In each experiment, 30 µg of protein were loaded for each CL tested, and the proteins obtained from different CL stages were loaded on the same gel. For quantification, an initial screening was performed on blots with Hyperfilm (Amersham, Piscataway, NJ) using different exposure times to optimize the signal. The levels of protein were analyzed by densitometry [26]; optical density data are expressed as arbitrary units ± SEM (n = 4–5 CL per stage of the luteal phase). The density in each VEGF band was normalized to the density of the ß-actin band that was used as an internal control.
In addition, VEGF proteins were analyzed in a pool of conditioned media (CM) from cultured luteal cells isolated from CL at the early, mid, and late luteal phases (see next section). Proteins were concentrated using a 10 000-Mr cutoff membrane (Microcon Centrifugal Filter Devices, Millipore, Burlington, MA). Western blot analysis was performed as described above.
Isolation and Serum-Free Culture of Luteal Cells
Collagenase-dispersed luteal cells were prepared from CL obtained at the early, mid, and late luteal phases as described previously [27] and placed in fibronectin (Sigma Chemical Co., St. Louis, MO)-coated, 96-well plates (40 000 cells/well; Costar; Corning, Inc., Corning, NY) containing Dulbecco modified Eagle medium/F-12 medium supplemented with insulin (5 µg/ml), transferrin (5 µg/ml), selenium (5 ng/ml), aprotinin (10 µg/ml), and low-density lipoprotein (25 µg/ml; all from Sigma) at 20% O2, 5% CO2 in air at 37°C [13]. After 24 h, cell cultures were transferred to atmospheres of either 20%, 5%, or 0% O2 in control medium with or without 100 ng/ml of human LH (AFP-4261A; Pituitary Network Assoc., Thousand Oaks, CA) or 100 mM CoCl2 (Sigma) as described previously in studies of macaque granulosa cells [14]. After 48-h exposure to various O2 atmospheres and treatments, media were collected and assayed for VEGF (Quantikine Human VEGF ELISA; R&D Systems; validated for macaque VEGF [13]) and for P4 (Elecsys 2010 [18]) as described above. In all experiments, cell numbers (DNA content) in wells were determined 48 h after treatment using the crystal violet assay [14].
Statistical Analysis
Statistical tests were performed using the SigmaStat software package (SPSS, Chicago, IL). Differences in VEGF mRNA and protein levels between stages of the luteal phase were analyzed using one-factor ANOVA followed by the Student-Neuman-Keuls method or Dunn test. Differences in VEGF and P4 levels between treatment groups within a stage of the luteal phase were determined by one-way ANOVA using a complete randomized block design followed by multiple-range tests to determine differences. Differences were considered to be significant at P < 0.05.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
When cDNAs from macaque CL at all stages (early through very late luteal phase) were amplified using VEGF primers that hybridize with the transcripts that encode six of the seven isomers (VEGF 206, 189, 183, 165, 145, and 121) (Fig. 1), all the PCR products corresponded to the mRNAs for VEGF 165 or 121. The products were inserted into a plasmid-based vector and transfected into the appropriate bacterial host. The resulting plasmids from individual bacteria clones were sequenced, and from nine plasmids, either the partial cDNA for VEGF 165 (n = 5) or VEGF 121 (n = 4) was identified. Both isoforms possessed 98% identity with the corresponding cDNAs for the human VEGF isoforms.
Subsequently, the RACE technique was employed to determine whether the mRNA encoding VEGF 148 isoform (which is missing exon 8) (Fig. 1) is also expressed in the macaque CL and to confirm the RT-PCR results. Again, the cDNA products evident following agarose gel electrophoresis were limited to two bands, corresponding to VEGF 165 and 121 (data not shown).
Semiquantitative RT-PCR Analysis of VEGF 165 and 121 mRNAs
Figure 2 summarizes the levels of VEGF mRNAs in macaque CL at different stages of the luteal phase during the natural menstrual cycle. Levels of VEGF 165 mRNA were appreciable at the early stage, increased 2.3-fold (P < 0.05) by the mid-late stage, and then declined (P < 0.05) in the later stages. Levels of VEGF 121 mRNA were limited in the early stage, but they increased significantly (6.6-fold) by the midluteal phase, peaked at the mid-late luteal phase, and then declined (P < 0.05) by the very late luteal phase. The levels of VEGF 165 and 121 mRNAs correlated positively (r = 0.51, P < 0.02 and r = 0.50, P < 0.03, respectively) with serum P4 levels on the day of CL collection (data not shown).
Although the levels of VEGF mRNAs were expressed relative to PPIA mRNA, the ratio of VEGF 165 to VEGF 121 mRNAs can be depicted (Fig. 3) throughout the luteal phase. A 35-fold greater expression of VEGF 165 mRNA was observed in the early luteal phase, but the ratio was variable. Nevertheless, the ratio declined (P < 0.05) fivefold by the midluteal phase, and it remained between 5 and 10 in favor of VEGF 165 mRNA through the later stages.
|
Western Blot Analysis of VEGF 165 and 121 Proteins
Western blot analysis (Fig. 4) resulted in two distinct bands of the expected sizes for VEGF 165 and 121. When normalized to ß-actin, a protein for which content was invariant during the CL life span, VEGF 165 levels were two- to fourfold higher than those of VEGF 121 in CL throughout the luteal phase. Levels of VEGF 165 were significantly higher in the early luteal phase, declined at the midluteal stage, and were lowest from mid-late luteal phase onward to menstruation. A similar pattern was observed for VEGF 121, except that levels did not decline between the early and mid stages.
|
A single, broad band, spanning the size range of VEGF 165 to 121, was observed in CM (Fig. 4) from cultures of macaque luteal cells.
VEGF Production by Macaque Luteal Cells In Vitro: Effects of LH and Hypoxia
After an initial plating interval, dispersed cell preparations from CL produced readily detectable levels of VEGF during 48 h of culture in control (serum-free, 20% O2) conditions (Table 1). However, levels appeared to decline as the luteal phase advanced, with luteal cells from the late stage producing lower (P < 0.05) levels of VEGF than cells from the early luteal phase. Notably, the presence of a receptor-saturating concentration of LH did not increase VEGF levels in cultures of luteal cells from any stage. In contrast, exposure to hypoxic (0% O2) conditions significantly increased VEGF levels in cultures of luteal cells from CL at the early, mid, or late luteal phase.
|
In comparison, P4 levels (Table 1) also declined as the luteal phase advanced, with luteal cells from the midluteal stage producing less (P < 0.05) than those from the early stage. Exposure to LH increased (P < 0.05) P4 levels by four- to fivefold in cultures of cells from the mid and late luteal phase, but not in those from the early stage. In contrast, hypoxic conditions suppressed (P < 0.05) P4 levels in control cultures of cells from the early luteal phase, but not in those from other stages.
Figure 5 summarizes VEGF (Fig. 5A) and P4 (Fig. 5B) levels in cell cultures prepared from the CL at the late luteal phase and incubated in various O2 concentrations or with CoCl2. Pharmacologic hypoxia because of cobalt exposure increased (P < 0.05) VEGF levels in the presence of 20% or 5% O2 concentrations. Also, reducing the oxygen tension increased VEGF levels; at 0% O2, levels were fivefold higher (P < 0.05) than those at 20% O2. Levels of VEGF in the presence of Co+2 or 0% O2 were comparable. Similar results were obtained with luteal cells from the early and midluteal phases (not shown), but the 5% O2 concentration significantly increased (P < 0.05) VEGF levels. Addition of LH, either alone or to any of the above treatment groups, did not alter VEGF levels in cell cultures from the late (Fig. 5A), mid (not shown), or early (not shown) luteal phase.
|
Cobalt exposure significantly decreased P4 levels in cell cultures prepared from CL at the late luteal phase in the presence of LH (Fig. 5B) at 20% or 5% O2 concentrations. However, cobalt did not alter P4 levels in the absence of LH (control vs. CoCl2). Similar results were observed on reducing the oxygen concentration. Although 5% O2 had little effect, 0% O2 reduced (P < 0.05) LH-stimulated P4 levels compared to those in the 20% O2 environment. Similar results were obtained with cells from the early and midluteal phase (not shown), except that Co+2 or 0% O2 elicited a more pronounced (P < 0.05) suppression of P4 levels in cultures not incubated with LH (Table 1).
The DNA analyses of cell cultures from all stages of the luteal phase, after 48-h exposure to the various conditions (20% to 0% oxygen, CoCl2) and with or without LH, revealed no significant differences among treatment groups (data not shown).
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The current findings are consistent with reports that VEGF 121 and 165 mRNAs were the predominant transcripts detected in whole ovaries and luteinizing granulosa cells of rats 1–4 h after administering an ovulatory hCG bolus [15] and in granulosa cells [28] and CL [29, 30] from sheep and cows. Examples can be cited in which VEGF 121 is the primary isoform expressed in cells/tissues [31]. However, evidence that VEGF 165 mRNA and protein levels typically were greater than those for VEGF 121 in the macaque CL is similar to that from the study by Redmer et al. [30], in which the latter represented about one-third of VEGF expression in the ovine CL. Notably, VEGF 145 mRNA was not detected in the CL, despite evidence that this isoform is produced by human luteinizing granulosa cells [16], reproductive tract carcinomas [32], the placenta [9], and the blastocyst [33]. Also, despite reports of weak expression of VEGF 189 mRNA in the CL of domestic animals [29, 30], we were unable to detect a signal by RT-PCR from primate luteal tissue. Because evidence exists that P4 selectively increases the expression of VEGF 189 mRNA in the human uterus [12] and several progestin-regulated processes were recently discovered in the primate CL [34], we hypothesized that VEGF 189 would be dynamically expressed in macaque luteal tissue—but this does not appear to be the case in the macaque (present study) or human [16]. Rather, it appears that the larger, basic VEGF 189 and 209 isoforms that are not readily secreted but are completely sequestered at the cell surface and ECM [5, 9] are not major products of the CL at any stage of the menstrual cycle.
Collectively, the data suggest that VEGF 121 and 165 constitute the bioactive forms within the primate CL. Both VEGF isoforms interact with the two VEGF receptors, FLT1 (also known as VEGFR-1) and KDR (also known as VEGFR-2) [5, 9]. However, recent evidence suggests that additional molecules on the endothelial cell surface, notably the neuropilin (NRP) 1 and NRP2, can serve as coreceptors for VEGF 165, thereby selectively enhancing the binding and actions of this isoform [35, 36]. Both NRP1 and NRP2 were recently detected in the rat uterus [37], and we have evidence for their presence in the macaque CL (unpublished data). Our findings that VEGF 165 expression and protein levels were greater than those for VEGF 121 suggests that this VEGF isoform is the major regulator of angiogenesis and vascular function during the life span of the CL. Nevertheless, further studies are needed to evaluate the actions of VEGF 165 versus those of VEGF 121 in luteal tissue; recent experiments on mice expressing single VEGF isoforms (VEGF120/120, VEGF164/164, and VEGF188/188 mice [11, 38]) demonstrate overlapping as well as isoform-specific functions in such diverse processes as retinal vascular development and bone development [5]. Whether the higher ratio of VEGF 165 to VEGF 121 in macaque CL during development in the early luteal phase is biologically significant remains unknown.
The current data extend our previous observation [23] of dynamic VEGF expression in the macaque CL during luteal life span by establishing that the rise in mRNA levels from the early to mid-late luteal phase results from transcription of the VEGF 165 and 121 mRNAs. Previous investigators have not agreed on whether VEGF mRNA levels change or remain constant in the CL during the ovarian cycle in primate species [23, 39]. Nevertheless, our experiments suggest that such patterns of RNA expression do not necessarily portray the pattern of VEGF protein produced within the CL (Fig. 4) or secreted by luteal cells (Table 1) during the luteal life span. Under control conditions, VEGF levels produced by dispersed cells from the macaque CL decreased as a function of age in the menstrual cycle (i.e., from the early through late luteal phase). Although these in vitro studies employed short-term culture conditions, it is possible that cell activity does not reflect the in vivo situation. However, the pattern of declining VEGF production during the luteal phase is consistent with earlier evidence that immunocytochemical staining for VEGF in the macaque CL was intense during the early luteal phase and diminished by the later stages before menses [23]. Thus, these data, as well as our earlier findings of divergence in VEGF mRNA and protein levels in the pre- and periovulatory follicle [40], support the concept that the level of VEGF produced by luteinizing granulosa cells and luteal cells in the primate ovary is regulated at both the transcriptional and posttranscriptional levels.
To our knowledge, the present study is the first examination of VEGF production by luteal cells in vitro, and the evidence suggests that following luteinization, the cells in the CL do not respond acutely (24–48 h) to gonadotropin with enhanced VEGF secretion. The observation that dispersed cells from the macaque CL did not respond to the luteotropic hormone LH with enhanced VEGF production was unexpected. It generally is believed that the midcycle LH surge promotes VEGF production by luteinizing granulosa cells in many [15, 16], but not all [41, 42], species, and we have reported previously that exposure to LH or chorionic gonadotropin increased VEGF production by nonluteinized granulosa cells from macaque preovulatory follicles by one to two orders of magnitude [13]. Evidence from primate species, wherein LH/chorionic gonadotropin are the primary luteotropic hormones, suggests that LH withdrawal (via administration of a GnRH antagonist [43]) or exposure to chorionic gonadotropin (mimicking CL rescue in early pregnancy [39]) decreased or increased, respectively, VEGF mRNA expression by the CL in vivo. The lack of an effect of LH on VEGF production was not a result of the luteal cell's general insensitivity to LH (e.g., an artifact of enzymatic tissue dispersion), because P4 production increased by four- to fivefold in the presence of LH after the early (post-LH surge) interval. However, we cannot rule out specific lesions in LH-sensitive VEGF production because of cell dispersion or culture. Alternatively, the divergence with the results of in vivo studies may relate to the sampling interval; notably, changes in VEGF expression were noted after 3 days, but not after 1 or 2 days, of GnRH antagonist treatment [43] and after 6–8 days of exposure to chorionic gonadotropin [39]. Thus, the gonadotropin effects in vivo may be indirect, resulting from other actions in the days following LH depletion or chorionic gonadotropin repletion.
Our data are consistent with a model of hypoxic stress [17] stimulating VEGF production within the CL, either to promote angiogenesis or to maintain the microvasculature in developing or functional luteal tissue, respectively. Reduced O2 tension or pharmacologic (e.g., cobalt) hypoxia increases VEGF mRNA or protein expression in a number of cell types or tissues, including reproductive organs, such as the uterus [44]. The discovery that the genes for VEGF and its receptor KDR (VEGF-R1) contain a hypoxia-response element that binds the hypoxia-inducible transcription factor HIF-1 [45] established a fundamental link between oxygen availability and VEGF expression/action in physiologic (e.g., primate menstruation and endometrial repair) and pathologic (e.g., tumor growth and retinopathy) angiogenesis [46]. However, we recently reported [14] that macaque granulosa cells isolated from preovulatory follicles either before or 27 h after exposure to an ovulatory gonadotropin (hCG) stimulus did not respond in vitro to reduced O2 tension or cobalt with increased VEGF production. We speculated that in the developing primate antral follicle, VEGF production by mural granulosa cells was low because of a lack of response to hypoxia and was regulated primarily by the midcycle gonadotropin surge. Collectively, the data suggest that following the action by LH at midcycle, the local O2 milieu is a primary regulator of VEGF production by luteinizing [47] or luteinized (present study) cells in the primate CL. It remains unclear why VEGF protein and mRNA levels decline as the primate CL ages in the menstrual cycle, but it could involve both endocrine factors (e.g., luteotropic LH) and local factors (O2 tension and insulin-like growth factors [14]).
Unlike VEGF production, hypoxic conditions reduced P4 production by luteal cells either in the absence of LH when basal secretion was high (i.e., early luteal phase) (Table 1) or in the presence of LH (all luteal stages; e.g., late luteal phase, as shown in Fig. 5). Because P4 synthesis requires a member of the cytochrome P-450 enzyme family (CYP11A or P-450 side-chain cleavage) that acts to insert one atom of oxygen into their products [48], it is not surprising that a pharmacologic competitor, such as cobalt or carbon monoxide, or low oxygen tension reduces P4 levels in short-term cultures of granulosa [14] or luteal (present study) cells. Considering the pronounced effects on LH-stimulated steroidogenesis, we cannot rule out other effects on LH-stimulated signal transduction (e.g., cAMP), cholesterol transport (e.g., StAR), or other mitochondrial functions.
In summary, these findings establish the dynamic and selective expression of VEGF isoforms in the macaque CL during the luteal life span in the natural menstrual cycle. Further studies are needed to elucidate the complementary and/or overlapping roles of VEGF 165 versus VEGF 121 during the development, function, and regression of the primate CL. Also, evidence suggests that the primary regulation of VEGF production changes as follicular granulosa cells differentiate into luteal cells, with LH losing its acute stimulatory activity and hypoxia gaining this capacity. How endocrine and local factors control the pattern of VEGF production at the cell or tissue level during the luteal life span awaits further investigation.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
2 Correspondence: Richard L. Stouffer, Division of Reproductive Sciences, Oregon National Primate Research Center, OHSU West Campus, 505 NW 185th Ave., Beaverton, OR 97006. stouffri{at}ohsu.edu
3 Current Address: Instituto de Biologia y Medicina Experimental, Obligado 2490, 1428 Buenos Aires, Argentina
4 Current Address: West Valley Fertility Center, Glendale, AZ 85308
Received: 11 January 2005.
First decision: 10 February 2005.
Accepted: 27 June 2005.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  S. van den Driesche, M. Myers, E. Gay, K. J. Thong, and W. C. Duncan HCG up-regulates hypoxia inducible factor-1 alpha in luteinized granulosa cells: implications for the hormonal regulation of vascular endothelial growth factor A in the human corpus luteum Mol. Hum. Reprod., August 1, 2008; 14(8): 455 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Duncan, S. van den Driesche, and H. M. Fraser Inhibition of Vascular Endothelial Growth Factor in the Primate Ovary Up-Regulates Hypoxia-Inducible Factor-1{alpha} in the Follicle and Corpus Luteum Endocrinology, July 1, 2008; 149(7): 3313 - 3320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Bogan, M. J. Murphy, R. L. Stouffer, and J. D. Hennebold Systematic Determination of Differential Gene Expression in the Primate Corpus Luteum during the Luteal Phase of the Menstrual Cycle Mol. Endocrinol., May 1, 2008; 22(5): 1260 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nishimura, J. Komiyama, Y. Tasaki, T. J. Acosta, and K. Okuda Hypoxia Promotes Luteal Cell Death in Bovine Corpus Luteum Biol Reprod, March 1, 2008; 78(3): 529 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Stanek, S. M. Borman, T. A. Molskness, J. M. Larson, R. L. Stouffer, and P. E. Patton Insulin and Insulin-Like Growth Factor Stimulation of Vascular Endothelial Growth Factor Production by Luteinized Granulosa Cells: Comparison between Polycystic Ovarian Syndrome (PCOS) and Non-PCOS Women J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2726 - 2733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.S. Robinson, L.T. Nicklin, A.J. Hammond, D. Schams, M.G. Hunter, and G.E. Mann Fibroblast Growth Factor 2 Is More Dynamic than Vascular Endothelial Growth Factor A During the Follicle-Luteal Transition in the Cow Biol Reprod, July 1, 2007; 77(1): 28 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kisliouk, A. Friedman, E. Klipper, Q.-Y. Zhou, D. Schams, N. Alfaidy, and R. Meidan Expression Pattern of Prokineticin 1 and Its Receptors in Bovine Ovaries During the Estrous Cycle: Involvement in Corpus Luteum Regression and Follicular Atresia Biol Reprod, May 1, 2007; 76(5): 749 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Trousdale, S. V. Pollak, J. Klein, L. Lobel, Y. Funahashi, N. Feirt, and J. W. Lustbader Single-Chain Bifunctional Vascular Endothelial Growth Factor (VEGF)-Follicle-Stimulating Hormone (FSH)-C-Terminal Peptide (CTP) Is Superior to the Combination Therapy of Recombinant VEGF plus FSH-CTP in Stimulating Angiogenesis during Ovarian Folliculogenesis Endocrinology, March 1, 2007; 148(3): 1296 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tropea, F. Miceli, F. Minici, F. Tiberi, M. Orlando, M. F. Gangale, F. Romani, S. Catino, S. Mancuso, P. Navarra, et al. Regulation of Vascular Endothelial Growth Factor Synthesis and Release by Human Luteal Cells in Vitro J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2303 - 2309. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||
